1. Body mass index and risk of obesity-related conditions in a cohort of 2.9 million people: Evidence from a UK primary care database.
- Author
-
Haase CL, Eriksen KT, Lopes S, Satylganova A, Schnecke V, and McEwan P
- Abstract
Objective: Obesity rates in the United Kingdom are some of the highest in Western Europe, with considerable clinical and societal impacts. Obesity is associated with type 2 diabetes (T2D), osteoarthritis, cardiovascular disease, and increased mortality; however, relatively few studies have examined the occurrence of multiple obesity-related outcomes in the same patient population. This study was designed to examine the associations between body mass index (BMI) and a broad range of obesity-related conditions in the same large cohort from a UK-representative primary care database., Methods: Demographic data and diagnosis codes were extracted from the Clinical Practice Research Datalink GOLD database in January 2019. Adults registered for ≥ 3 years were grouped by BMI, with BMI 18.5-24.9 kg/m
2 as reference group. Associations between BMI and 12 obesity-related outcomes were estimated using Cox proportional hazard models, adjusted for age, sex, and smoking., Results: More than 2.9 million individuals were included in the analyses and were followed up for occurrence of relevant outcomes for a median of 11.4 years during the study period. Generally, there was a stepwise increase in risk of all outcomes with higher BMI. Individuals with BMI 40.0-45.0 kg/m2 were at particularly high risk of sleep apnea (hazard ratio [95% confidence interval] vs. reference group: 19.8 [18.9-20.8]), T2D (12.4 [12.1-12.7]), heart failure (3.46 [3.35-3.57]), and hypertension (3.21 [3.15-3.26])., Conclusions: This study substantiates evidence linking higher BMI to higher risk of a range of serious health conditions, in a large, representative UK cohort. By focusing on obesity-related conditions, this demonstrates the wider clinical impact and the healthcare burden of obesity, and highlights the vital importance of management, treatment approaches, and public health programs to mitigate the impact of this disease., Competing Interests: Christiane L. Haase, Kirsten T. Eriksen, Sandra Lopes, Altynai Satylganova and Volker Schnecke are employees of Novo Nordisk A/S. Altynai Satylganova and Sandra Lopes are also shareholders of Novo Nordisk A/S. Phil McEwan is an employee of Health Economics and Outcomes Research Ltd. Phil McEwan did not receive funding for this collaboration. HEOR Ltd have received funding from Novo Nordisk A/S for work conducted on previous studies., (© 2020 The Authors. Obesity Science & Practice published by World Obesity and The Obesity Society and John Wiley & Sons Ltd.)- Published
- 2020
- Full Text
- View/download PDF